Momenta Pharmaceuticals (MNTA) Marked As A Dead Cat Bounce Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Momenta Pharmaceuticals ( MNTA) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Momenta Pharmaceuticals as such a stock due to the following factors:

  • MNTA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $28.3 million.
  • MNTA has traded 59,213 shares today.
  • MNTA is up 7.3% today.
  • MNTA was down 5.2% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MNTA with the Ticky from Trade-Ideas. See the FREE profile for MNTA NOW at Trade-Ideas

More details on MNTA:

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently there are 4 analysts that rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

The average volume for Momenta Pharmaceuticals has been 945,900 shares per day over the past 30 days. Momenta has a market cap of $1.1 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.85 and a short float of 14.2% with 4.49 days to cover. Shares are up 52.9% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Teva Must Clear Three Big Hurdles to Reclaim Its Perch

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Sarepta Leads Biotech Movers on Voucher Deal News